FOI 7382 - Drugs used

Date: 30 May 2022 to 30 May 2025

How many patients were treated by your Trust (for any condition) in the last 3 months with the following drugs:

Adalimumab (Amgevita)

Adalimumab (Humira)

Adalimumab (Hyrimoz)

Adalimumab (Idacio)

Adalimumab (Imraldi)

Question 2.

How many patients were treated in the last 3 months by the Rheumatology department (for any condition) with the following drugs:

Adalimumab (Amgevita)

Adalimumab (Humira)

Adalimumab (Hyrimoz)

Adalimumab (Idacio)

Adalimumab (Imraldi)

Question 3.

How many patients were treated in the last 3 months by the Dermatology department (for any condition) with the following drugs:

Adalimumab (Amgevita)

Adalimumab (Humira)

Adalimumab (Hyrimoz)

Adalimumab (Idacio)

Adalimumab (Imraldi)

 

  • Request ID:
    7382
  • Category:
    Clinical - Drugs
  • Response:

    May 2022

    Freedom of Information Request: reference 7382

     

    Thank you for your recent request under the Freedom of Information Act 2000.

     

    The information you have requested is as follows:

     

     

    How many patients were treated by your Trust (for any condition) in the last 3 months with the following drugs: Please see below table

    Adalimumab (Amgevita)

    Adalimumab (Humira)

    Adalimumab (Hyrimoz)

    Adalimumab (Idacio)

    Adalimumab (Imraldi)

     

    Question 2.

    How many patients were treated in the last 3 months by the Rheumatology department (for any condition) with the following drugs: Please see below table

    Adalimumab (Amgevita)

    Adalimumab (Humira)

    Adalimumab (Hyrimoz)

    Adalimumab (Idacio)

    Adalimumab (Imraldi)

     

    Question 3.

    How many patients were treated in the last 3 months by the Dermatology department (for any condition) with the following drugs: There have been no issues to dermatology

    Adalimumab (Amgevita)

    Adalimumab (Humira)

    Adalimumab (Hyrimoz)

    Adalimumab (Idacio)

    Adalimumab (Imraldi)

     

     

    Below is all issues in the last 3 months. 

     

    Please note Reporting period is 27/02/2022 to 27/05/2022

     

    Speciality

    Drug

    Total Number of Patients

    Gastroenterology

    ADALIMUMAB (AMGEVITA) - HOMECARE

    <5

    ADALIMUMAB (HUMIRA) - HOMECARE

    11

    ADALIMUMAB (IMRALDI) - HOMECARE

    104

    Rheumatology

    ADALIMUMAB (AMGEVITA) - HOMECARE

    <5

    ADALIMUMAB (HUMIRA) - HOMECARE

    68

    ADALIMUMAB (IMRALDI) - HOMECARE

    294